• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OCX

    Oncocyte Corporation

    Subscribe to $OCX
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.

    IPO Year:

    Exchange: AMEX

    Website: oncocyte.com

    Peers

    $BIOC

    Recent Analyst Ratings for Oncocyte Corporation

    DatePrice TargetRatingAnalyst
    3/28/2025$5.00Buy
    Lake Street
    5/24/2022Overweight → Equal-Weight
    Stephens
    3/14/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    3/11/2022$11.00 → $6.00Buy
    Lake Street
    3/11/2022$5.00 → $4.00Buy
    Needham
    1/7/2022$3.10Overweight
    Stephens & Co.
    1/6/2022$3.10Overweight
    Piper Sandler
    12/16/2021$7.00 → $5.00Buy
    Needham
    11/10/2021$8.00 → $7.00Buy
    Needham
    See more ratings

    Oncocyte Corporation SEC Filings

    See more
    • Oncocyte Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Oncocyte Corp (0001642380) (Filer)

      4/17/25 5:17:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 424B3 filed by Oncocyte Corporation

      424B3 - Oncocyte Corp (0001642380) (Filer)

      4/8/25 6:10:29 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Oncocyte Corporation

      EFFECT - Oncocyte Corp (0001642380) (Filer)

      4/8/25 12:15:23 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-1 filed by Oncocyte Corporation

      S-1 - Oncocyte Corp (0001642380) (Filer)

      3/31/25 1:25:34 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-K filed by Oncocyte Corporation

      10-K - Oncocyte Corp (0001642380) (Filer)

      3/24/25 4:16:17 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Oncocyte Corp (0001642380) (Filer)

      3/24/25 4:10:15 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Corporation filed SEC Form 8-K: Leadership Update

      8-K - Oncocyte Corp (0001642380) (Filer)

      3/10/25 4:05:26 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oncocyte Corporation

      SCHEDULE 13G/A - Oncocyte Corp (0001642380) (Subject)

      3/4/25 7:06:30 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form D filed by Oncocyte Corporation

      D - Oncocyte Corp (0001642380) (Filer)

      2/24/25 6:03:12 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oncocyte Corporation

      SCHEDULE 13G/A - Oncocyte Corp (0001642380) (Subject)

      2/14/25 2:41:23 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Oncocyte Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OncoCyte with a new price target

      Lake Street initiated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00

      3/28/25 8:35:58 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • OncoCyte downgraded by Stephens

      Stephens downgraded OncoCyte from Overweight to Equal-Weight

      5/24/22 8:51:33 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • OncoCyte downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded OncoCyte from Overweight to Sector Weight

      3/14/22 7:21:22 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lake Street reiterated coverage on OncoCyte with a new price target

      Lake Street reiterated coverage of OncoCyte with a rating of Buy and set a new price target of $6.00 from $11.00 previously

      3/11/22 10:18:27 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Needham reiterated coverage on OncoCyte with a new price target

      Needham reiterated coverage of OncoCyte with a rating of Buy and set a new price target of $4.00 from $5.00 previously

      3/11/22 5:57:30 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Stephens & Co. initiated coverage on OncoCyte with a new price target

      Stephens & Co. initiated coverage of OncoCyte with a rating of Overweight and set a new price target of $3.10

      1/7/22 5:45:55 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Piper Sandler resumed coverage on OncoCyte with a new price target

      Piper Sandler resumed coverage of OncoCyte with a rating of Overweight and set a new price target of $3.10

      1/6/22 7:42:24 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Needham reiterated coverage on OncoCyte with a new price target

      Needham reiterated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      12/16/21 4:35:30 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Needham reiterated coverage on OncoCyte with a new price target

      Needham reiterated coverage of OncoCyte with a rating of Buy and set a new price target of $7.00 from $8.00 previously

      11/10/21 5:56:58 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Needham resumed coverage on OncoCyte with a new price target

      Needham resumed coverage of OncoCyte with a rating of Buy and set a new price target of $8.00

      3/17/21 7:24:41 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Oncocyte Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      12/9/24 5:30:06 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Oncocyte Corporation

      SC 13G - Oncocyte Corp (0001642380) (Subject)

      11/14/24 1:26:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      10/24/24 12:13:28 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Oncocyte Corporation

      SC 13G - Oncocyte Corp (0001642380) (Subject)

      10/9/24 5:03:13 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Oncocyte Corporation

      SC 13G - Oncocyte Corp (0001642380) (Subject)

      4/22/24 1:30:07 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Oncocyte Corporation (Amendment)

      SC 13D/A - Oncocyte Corp (0001642380) (Subject)

      4/15/24 7:26:25 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Oncocyte Corporation (Amendment)

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      2/14/24 5:03:19 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Oncocyte Corporation (Amendment)

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      2/14/24 3:47:19 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Oncocyte Corporation (Amendment)

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      4/14/23 4:31:05 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Oncocyte Corporation (Amendment)

      SC 13D/A - Oncocyte Corp (0001642380) (Subject)

      4/7/23 10:38:25 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Oncocyte Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 7:00:32 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 5:00:15 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/10/25 8:43:04 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $1,839 worth of shares (915 units at $2.01) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/4/25 4:45:27 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $8,438 worth of shares (4,198 units at $2.01) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      1/31/25 5:00:11 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $34,114 worth of shares (16,055 units at $2.12) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      1/15/25 5:00:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $192,166 worth of shares (90,219 units at $2.13) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      12/27/24 9:49:20 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Arno Andrew bought $26,350 worth of shares (12,500 units at $2.11), increasing direct ownership by 18% to 81,554 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      12/26/24 6:17:58 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer James Andrea S. bought $45,800 worth of shares (20,000 units at $2.29), increasing direct ownership by 59% to 53,670 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      12/9/24 8:00:20 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer James Andrea S. bought $100,000 worth of shares (33,670 units at $2.97) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      10/4/24 7:40:56 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Oncocyte Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer James Andrea S.

      4 - Oncocyte Corp (0001642380) (Issuer)

      3/28/25 4:05:18 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by VP ACCT, Cntlr, Treasurer, PAO Liu James Yang

      4 - Oncocyte Corp (0001642380) (Issuer)

      3/28/25 4:05:17 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by CEO and President Riggs Josh

      4 - Oncocyte Corp (0001642380) (Issuer)

      3/28/25 4:05:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 7:00:32 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 5:00:15 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/10/25 8:43:04 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $1,839 worth of shares (915 units at $2.01) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/4/25 4:45:27 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $8,438 worth of shares (4,198 units at $2.01) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      1/31/25 5:00:11 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $34,114 worth of shares (16,055 units at $2.12) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      1/15/25 5:00:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $192,166 worth of shares (90,219 units at $2.13) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      12/27/24 9:49:20 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Oncocyte Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

      Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in BerlinSupports market expansion for testing of high-risk patient populationNew findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced the publication of new and positive data regarding its proprietary blood-based transplant rejection assay. The publication, "Association of Blood Donor-derived Cell-free DNA Levels with Banff Scores and Histopathological Lesions in Kidney Allograft Biopsies: Results From an Observational Study," is c

      4/29/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

      IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte's innovative diagnostic technologies and will highlight the company's progress toward commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach, positioning Oncocyte

      4/2/25 8:45:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

      Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded clinical kitted product development with $50+ million in equity raisesAdvanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the

      3/24/25 4:05:00 PM ET
      $BIO
      $OCX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

      IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q4 2024 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About OncocyteOncocyte is a leading

      3/18/25 4:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

      IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule. Event: BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2025Dates: February 11-12, 2025Location: Snowbird, Utah, USA About OncocyteOncocyte is a leading diagnostics te

      2/11/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Prices $29.1 Million Equity Offering

      Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial LaunchStrategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering ("Registered Direct Offering") and concurrent private placement ("PIPE Offering"). The Company's five largest shareholders, including Bio-Rad Laboratories, Inc., (NYSE:BIO) ("Bio-Rad"), a key strategic partner of the Company, led the funding round. The round is expected

      2/10/25 8:30:00 AM ET
      $BIO
      $OCX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Oncocyte Corporation Financials

    Live finance-specific insights

    See more
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

      IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q4 2024 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About OncocyteOncocyte is a leading

      3/18/25 4:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

      Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phaseFDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX) ("Oncocyte" or the "Company"), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third quarter results: Fellow Shareholders, We are pleased to report that we are making considerable progress on two fronts that help de-risk our path to meaningful revenue. First, we are continuing to sign

      11/12/24 4:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

      IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call. The live webcast of the call may be accessed by visiting the "Even

      11/6/24 4:45:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

      Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders,We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood. On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United State

      8/8/24 4:05:00 PM ET
      $AXON
      $BIO
      $OCX
      Ordnance And Accessories
      Industrials
      Biotechnology: Laboratory Analytical Instruments
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

      IRVINE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on Thursday, August 8, 2024, at 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call. The live webcast of the call may be accessed by visiting the "Events & Presentations" section of the Com

      8/1/24 4:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

      Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with claims expansion IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine. Oncocyte's Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study (NCT05021484) of t

      5/30/24 4:47:51 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Reports First Quarter 2024 Financial Results

      IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc.On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD kits are under development for FDA submission.Raised $15.8 million in gross proceeds from equity private placement; as part of the financing, Bio-Rad purchased 8.99% of Oncocyte; new and existing investors invested as well.Reduced cash burn to $3.9 million, r

      5/15/24 4:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Oncocyte Corporation Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

      Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. In this part-time role, he will support a range of strategic and clinical goals for Oncocyte. Dr. Billings is a recognized pioneer in genomics and precision medicine with over 40 years of experience spanning academia, government,

      1/8/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

      NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (NASDAQ:OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025. Under the leadership of CEO Josh Riggs, Oncocyte is poised for a transformative period with its upcoming commercial launches. The company's flagship products, the VitaGraft™ Kidney diagnostic test and its research use only (RUO) GraftAssure

      6/24/24 12:41:19 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Appoints Andrea James as Chief Financial Officer

      IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. "We are thrilled to welcome Andrea as we approach the inflection point of commercial launch," Oncocyte CEO Josh Riggs said. "She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team. "We expect 2024 and 2025 t

      6/17/24 4:05:00 PM ET
      $AXON
      $OCX
      Ordnance And Accessories
      Industrials
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

      IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023. Since being named interim CEO in December, Riggs has successfully led the process of restructuring the Company by refocusing product strategy and reducing costs across the organization. Riggs also serves as President and joins the Company's Board of Directors. "Since his appointment as Interim CEO, Josh has worked quickly, collaboratively, and effectively to significantly reduce the Company's spend rate, has driven the restructuring of a number of strategic i

      3/2/23 9:00:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

      IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of Louis E. Silverman as an independent member of its board of directors, effective immediately. "I am pleased to announce the appointment of Lou as a member of our Board," said Andy Arno, Chair of Oncocyte's Board of Directors. "Lou's 25+-year track record of success as CEO in health care IT and health care services companies will assuredly be accretive to the Company's strategic goals. We are co

      11/30/22 6:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022

      IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of John Peter (JP) Gutfreund as an independent member of its board of directors, effective July 28, 2022. "We welcome JP to our Board of Directors at what we believe to be an important time in the life of Oncocyte, as we anticipate bringing three major products through reimbursement and to market over the next four quarters," said Ron Andrews, CEO of Oncocyte. "He brings a wealth of financial expe

      8/1/22 5:00:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer

      IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced the appointment of Gisela A. Paulsen, MPharm, to the role of Chief Operating Officer (COO). Paulsen brings with her over two decades of experience as a cross-functional leader, with an extensive scientific and operational background leading large-scale global change management and driving commercial and drug development innovation at global pharmaceutical and diagnostics companies. "We

      10/7/21 8:00:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care